Lecigimon

Levodopa/Carbidopa/Entacapone, the active ingredient in Lecigimon, is a Levodopa/Carbidopa/Entacapone combination presented as an oral tablet for intestinal use. It is indicated for the management of Parkinson's disease in adults, providing enhanced central dopaminergic stimulation and is commonly used as part of a comprehensive treatment regimen.

GNH USA supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical product, adhering to EU quality standards and regulatory requirements. The company provides the medication to hospitals, pharmacies and clinics worldwide, supporting reliable access to antiparkinson therapy.

Lecigimon, a Levodopa/Carbidopa/Entacapone combination, is used in the management of Parkinson's disease and related dopaminergic disorders. - Parkinson's disease (early stage): provides symptomatic relief of motor symptoms. - Parkinson's disease with motor fluctuations: reduces OFF periods and improves motor stability. - Advanced Parkinson's disease: enhances overall motor control and daily functioning.

Lecigimon may cause a range of adverse reactions. Common Side Effects: - Nausea: gastrointestinal discomfort often occurring after the first doses. - Dizziness: may be related to orthostatic blood pressure changes. - Orthostatic hypotension: drop in blood pressure upon standing, leading to light‑headedness. - Insomnia: difficulty falling or staying asleep. Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can be disabling. - Psychiatric disturbances: hallucinations, confusion, or mood changes. - Severe liver enzyme elevation: may indicate hepatic injury requiring monitoring.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood pressure: watch for orthostatic hypotension, especially during dose titration. - Assess liver function: periodic liver enzyme tests are recommended. - Evaluate psychiatric status: be alert for hallucinations or behavioral changes. - Adjust dose in renal impairment: consider reduced dosing or increased monitoring. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lecigimon can interact with other medicines, requiring careful management. Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may worsen confusion or cognitive impairment. - CNS depressants: can increase sedation and respiratory depression. Moderate Interactions (Monitor Closely): - Other dopaminergic agents: may amplify dyskinesia. - SSRIs or SNRIs: potential for serotonin syndrome. - Antihypertensive drugs: additive hypotensive effect may require dose adjustment.